Thyroid management
The most common mistake in midlife thyroid care is treating a slightly high thyroid-stimulating hormone (TSH) reading in someone who feels perfectly well. The biggest recent shift is the recognition that most "thyroid cancers" picked up on neck ultrasound would never have caused any harm.
Test your thyroid when you have a reason, not as a routine optimization marker. If a single TSH comes back mildly high and you feel fine, repeat it in 6–12 weeks rather than starting a pill, and don't ask for a "screening" neck ultrasound. Get iodine and selenium from food, skip kelp and megadose supplements, and fix a vitamin D level only if it is actually low.
A slightly high TSH is usually not a disease
The standard adult TSH range, roughly 0.45–4.5 mIU/L, came from a US population that included undiagnosed autoimmune thyroid disease; without those people the upper limit is closer to 2.5–3.0 mIU/L.[1] Using that lower cutoff, though, would label an estimated 22–28 million Americans as underactive overnight and trigger prescriptions that have not shown long-term benefits.[2]
The more useful fix is a range that moves with age. A 2025 analysis of US and Chinese data found that the top of the normal TSH range rises with age and varies by ethnic group. Using age-specific limits moved 48.5% of people labelled mildly underactive back into the normal range.[3] French endocrinologists use a simple rule for older adults: the upper limit is your age divided by 10, so 7.0 mIU/L at 70.[4] A TSH of 4.5 at 70 is not the same number as a TSH of 4.5 at 30.
The decisive trial randomized 737 adults aged 65 and over, each with a TSH of 4.60–19.99 mIU/L on two tests and normal thyroxine (T4), to levothyroxine or placebo. Treatment improved nothing: not thyroid symptoms, fatigue, thinking, grip strength, daily functioning or artery-wall thickness. Heart attacks and strokes were no less common either, but the trial was too small and short to test them properly.[5]
Many raised readings also fix themselves. Among 1,751 people with mildly raised TSH at a health-screening centre, 57.9% were back to normal over a median 36 months without treatment. TSH runs higher in winter and spring, and a repeat test in summer or autumn was about 1.4 times more likely to come back normal.[6] The same holds in people over 65: in the populations of two trials of older adults, TSH returned to normal within about a year in 61% after one high reading, and in 40% of those confirmed high on two tests at least three months apart. A lower starting TSH, negative TPO antibodies and a summer retest made this more likely, and the authors suggest a third test before treating.[7]
Guidelines carve out exceptions, but most rest on convention rather than trials. Pregnancy is the clearest case, and even there the evidence is thin: in pooled trials, levothyroxine during pregnancy may have lowered preterm births when TSH was above 4 mIU/L, but that result was not statistically clear, and treating before conception did not raise live-birth rates.[8] Many clinicians also treat a TSH that stays above 10 mIU/L, or clearly symptomatic younger adults. A BMJ guideline panel's strong recommendation against treatment excludes only women trying to conceive, people with TSH above 20 mIU/L, and possibly people with severe symptoms or aged 30 or younger.[9]
Too much thyroid hormone is the bigger risk
Overtreatment is where the harm is. In a large Dutch primary-care cohort, a suppressed TSH, whatever the cause, was linked to about 37% more atrial fibrillation,[10] and over-replacement also speeds bone loss. In people over 65, a TSH pushed low by too much thyroid hormone was linked to about 34% more new cognitive impairment and dementia.[11] These links are observational. And overtreatment is common: more than half of new levothyroxine prescriptions at three US academic centres did not meet evidence-based criteria.[12]
Long-lived people point the same direction. In an Ashkenazi Jewish cohort, 35.2% of centenarians had a TSH above 2.5 mIU/L, against 15.4% of younger controls,[13] and their children showed the same pattern, which suggests an inherited set point.[14] In a large Dutch population study of about 7,800 adults whose thyroid tests were all normal, those with a TSH in the top third of normal lived about 2.0 years (men) and 1.4 years (women) longer from age 50 than those in the bottom third. Those with free T4 in the top third of normal lived about 3.2 years (men) and 3.5 years (women) less. Much of the difference was in years free of cardiovascular disease.[15]
One proposed reason is that thyroid hormone turns up heat production, and with it the oxidative by-products that damage cells; a slightly slower engine may wear more slowly.[16]
This is not an argument for pushing your thyroid low. Mice held in a mild, stable underactive state live a normal lifespan, but with severe insulin resistance, fatty liver and aggressive liver cancer.[17] A mildly raised TSH in an older adult is probably adaptive. Deliberately suppressing thyroid function below the normal range risks the kind of metabolic damage seen in those mice.
Still tired on levothyroxine with normal blood tests
Roughly 5–15% of people on levothyroxine (synthetic T4) with a normal TSH still have symptoms, most often fatigue, weight trouble, poor memory and low mood.[18] The body has to convert T4 into the active hormone T3 inside tissues, and the leading but unproven explanation is that some people don't convert enough where it matters, so their blood looks fine while their tissues run short.[19]
T3 combination therapy, adding T3 to levothyroxine, helps a little on average. A 2024 pooled analysis of 16 trials found a statistically significant improvement of about 3 points on a 28-item psychological distress questionnaire, a real but modest shift; fatigue scales, cholesterol, heart rate and general quality of life often didn't budge.[20] A gene test (DIO2) once proposed to pick who benefits did not hold up in later studies,[21][22] and the American Thyroid Association recommends against using genetic tests to choose treatment.[23] Desiccated animal thyroid (Armour Thyroid, NP Thyroid) is popular with patients, but its trials are low quality.
If you try combination therapy, treat it as a supervised experiment: the European Thyroid Association advises that a specialist starts it and stops it if nothing improves after 3 months.[24] At correct doses the safety data are broadly reassuring, though the heart-failure estimate was borderline and the serious harms in case reports came from unregulated or compounded T3.[25] Monitor TSH so it isn't suppressed. It is not an upgrade for someone who feels fine on T4.
Hashimoto's: what selenium, vitamin D and diet can and can't do
In countries with enough iodine, most underactive thyroids are caused by Hashimoto's thyroiditis, a slow autoimmune attack on the gland marked by antibodies against thyroid peroxidase (TPO) and thyroglobulin. Women get it 4–10 times more often than men.[26] Several nutrients can shift the antibody levels; none has yet been shown to change how the disease turns out.
Selenium has the strongest data. Pooling 35 randomised trials, rated moderate-certainty, selenium supplements produced a moderate-to-large fall in TPO antibodies, though thyroglobulin antibodies did not change significantly.[27] Lower antibodies have not translated into feeling better. In the largest trial with a patient-centred outcome, 412 people already on levothyroxine took 200 µg selenium or placebo daily for a year; quality of life improved equally in both groups, and the small antibody drop didn't change their levothyroxine dose.[28] No trial has shown selenium delays the need for levothyroxine.
The safe margin is narrow. Europe's food-safety agency sets the adult upper limit at 255 µg a day from all sources, a margin below the intake at which extra hair loss appeared in a large trial; chronic excess also brings brittle nails and digestive upset.[29] In pooled trials, 200 µg a day raised the risk of type 2 diabetes by about 11%.[30] Brazil nuts are rich in selenium but vary widely; if you already eat them regularly, don't add a supplement on top.
Vitamin D shortfall tracks with higher antibodies,[31] but pooled trials are inconsistent. One 2024 network analysis found no clear antibody drop versus placebo over six months.[32] Another, pooling before-and-after changes from 10 trials, found TPO antibodies fell only in people who started low.[33] Claims that vitamin D receptor gene variants change the response come from small case-control studies, not trials.[34] Correct a low level (below 50 nmol/L, 20 ng/mL); a 2024 Endocrine Society guideline found no clear evidence for an optimal blood level and advises against routine testing without a reason.[35] See Vitamin D.
The rest is thin:
- Omega-3. Higher red-blood-cell levels of two omega-3 fats went with roughly 26–37% lower odds of Hashimoto's, but this is a snapshot association, not proof of protection.[36] See Omega-3.
- Lactose restriction, if you are lactose-intolerant. In one small uncontrolled study, 38 such patients on levothyroxine who cut out lactose for 8 weeks saw TSH fall, probably because the drug was absorbed better (absorption itself was not measured).[37] Worth considering if your dose keeps creeping up or your TSH is erratic.
- Autoimmune protocol, grain-free and gluten-free diets. In one uncontrolled study of 28 people, symptoms eased on the autoimmune protocol over 12 weeks, but thyroid tests did not clearly improve and TPO antibodies rose.[38] Pooling three randomized trials of gluten-free diets in people without celiac disease found no effect on TSH, thyroid hormones or inflammation, and mixed antibody results, at very low certainty.[39] Go gluten-free if you have celiac disease; otherwise these diets are optional.
- Soy. In trials soy does not change thyroid hormones, but in mildly underactive thyroid an isoflavone supplement tipped a few people into overt disease, and levothyroxine is best taken apart from soy. See Soy.
- Myo-inositol. No clear antibody benefit versus placebo.[40] In three small trials (288 people), adding it to selenium lowered TSH more than selenium alone, without changing antibodies.[41] Too thin to recommend.
Iodine: too little and too much both hurt
The thyroid needs iodine to make its hormones, and both shortage and excess disrupt it. The cleanest natural experiment compared two Danish towns, one with iodine-rich drinking water (139 µg/L) and one with almost none (2 µg/L).[42] Among residents aged 75–80, 26% in the iodine-poor town had a TSH below normal, a sign of an overactive gland, against 6% in the iodine-rich town; underactive thyroids ran the other way, 13% in the iodine-rich town against 6% in the iodine-poor one.[43] That fits a gland short of iodine growing nodules that make hormone on their own. Over 20 years, deaths were about 40% lower in the iodine-rich town, but only 428 people were followed to the end, so the size of that effect is indicative, not precise.[44]
Excess is the other common mistake. Kelp supplements and Lugol's solution can easily push intake past the adult upper limit of about 1,100 µg a day and cause iodine-induced hypothyroidism, especially in older people or those with existing thyroid disease. The American Thyroid Association advises against supplements above 500 µg a day.[45]
Adults need about 150 µg a day, and 220–290 µg in pregnancy and breastfeeding. Dairy, fish, eggs and iodized salt are the main sources. Where intake depends on food choice rather than fortified salt, it is fragile: it drops when people cut back on salt or move to plant-based diets, and it matters before pregnancy as well as during it, because shortage can harm the baby's brain development.[46] In one 2024 study of young Norwegians, vegans' median urinary iodine was under 50 µg/L, in the moderate-deficiency range.[47] If you eat little dairy or fish, use iodized salt at home or a supplement of about 150 µg. Not every multivitamin contains iodine, so check the label.
Most small thyroid cancers would never have harmed anyone
US papillary thyroid cancer diagnoses nearly quadrupled between 1975 and 2009, from 3.4 to 12.5 per 100,000, while deaths held at about 0.5 per 100,000.[48] Modelling estimates that 72–94% of US papillary thyroid cancers diagnosed between 1991 and 2019 were overdiagnoses: tumours that would never have caused symptoms. Women bore most of it, an estimated 13–17 overdiagnosed cases per 100,000 a year against 3–5 for men, largely because women get more neck imaging.[49]
The driver was high-resolution neck ultrasound in primary care, followed by needle biopsy of tiny nodules nobody could feel. The cost was several hundred thousand overdiagnosed cancers, many followed by thyroid removal, radioactive iodine and lifelong levothyroxine, plus the surgical risks of a damaged voice nerve and permanently low calcium. Since about 2014 diagnoses have fallen, fastest for tumours of 1 cm or less while those over 2 cm held steady, which is what you'd expect when doctors stop finding harmless tumours. Deaths among diagnosed patients still rose by about 1% a year from 2000 to 2018, a reminder that a small share of these cancers do matter.[50] See cancer screening for the same logic in breast and prostate.
That is why the US Preventive Services Task Force recommends against screening adults without symptoms for thyroid cancer, by neck exam or ultrasound.[51] Unless you had radiation to the head or neck in childhood, have a strong family history or inherited syndrome, or have a lump, hoarseness or swallowing trouble, a "screening" thyroid ultrasound is more likely to start a cascade than to help.
If a scan does turn up a small nodule, don't rush. The 2025 American Thyroid Association guideline says a needle biopsy is not routinely recommended for nodules of 1 cm or less that look low-risk on ultrasound. If a biopsy has already shown a papillary cancer of 1 cm or less, with no spread to lymph nodes and no growth outside the thyroid, the guideline says active surveillance (regular ultrasound instead of immediate surgery) may be offered to selected patients. That is a conditional recommendation on low-certainty evidence: an option to discuss, not a new standard.[52]
In the longest-running programme, at a Japanese hospital since 1993, 3,222 adults chose surveillance. About 5% of tumours had grown by 3 mm or more at 10 years, about 1–2% developed new lymph-node spread, roughly 1 in 8 people eventually chose or needed surgery, and nobody died of thyroid cancer.[53] These are self-selected patients looked at in hindsight, which is why the recommendation stays conditional. Ultrasound-guided ablation, which destroys the tumour through a needle, is a third route the guideline says may be considered; it is also conditional, with thin long-term data and results that depend heavily on the operator.[54][55]
For advanced cancer that keeps growing despite radioactive iodine, the guideline uses targeted drugs, with lenvatinib (usually started at 24 mg daily, with doses paused or reduced for side effects) preferred when there is no specific genetic target; tumours with certain gene fusions get a drug aimed at that alteration first.[56]
What to actually do
- Test TSH when there's a reason: fatigue, weight change, low mood, feeling cold, hair changes, slow recovery, abnormal cholesterol, fertility work-up, pregnancy, or as a one-off midlife baseline. Don't track it for "optimization"; see midlife labs for where it belongs on a panel.
- Read the result in context. A TSH of 4–6 mIU/L in a 65-year-old without symptoms is most likely normal for that age. Recheck a single abnormal value before treating.
- Add antibody tests when the picture is unclear. TPO and thyroglobulin antibodies separate true autoimmune disease from harmless drift, and antibody-positive people deserve closer follow-up even if TSH is borderline.
- On levothyroxine and still unwell? Rule out iron or B12 shortage, sleep apnea, depression, insomnia and overtraining before trying T3.
What's overrated
- Pushing TSH into an "optimal" 0.5–2.0 range when you feel fine. Long-lived people run the other way.
- "Adrenal-thyroid fatigue" protocols that combine desiccated thyroid, cortisol and unvalidated saliva tests. None has trial support, and several carry real harms.
Further reading
- Stott DJ et al. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism (TRUST). NEJM 2017.[57]
- Li Q et al. Thyroid Function Reference Intervals by Age, Sex, and Race: A Cross-Sectional Study. Ann Intern Med 2025.[58]
- Kim TH et al. Effect of seasonal changes on the transition between subclinical hypothyroid and euthyroid status. JCEM 2013.[59]
- Atzmon G et al. Extreme Longevity Is Associated with Increased Serum Thyrotropin. JCEM 2009.[60]
- Bano A et al. Association of Thyroid Function with Life Expectancy: The Rotterdam Study. JAMA Intern Med 2017.[61]
- Nassar M et al. Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism — systematic review and meta-analysis. BMC Endocr Disord 2024.[62]
- Wiersinga WM. T4+T3 Combination Therapy: An Unsolved Problem of Increasing Magnitude and Complexity. Endocrinol Metab 2021.[63]
- Huwiler VV et al. Selenium Supplementation in Patients with Hashimoto Thyroiditis — systematic review and meta-analysis of randomized clinical trials. Thyroid 2024.[64]
- Riis J et al. Long-term iodine nutrition is associated with longevity in older adults: a 20 years' follow-up of the Randers-Skagen study. Br J Nutr 2021 (epub 2020).[65]
- Francis DO et al. Overdiagnosis of Papillary Thyroid Cancer. JAMA Netw Open 2026.[66]
- Ringel MD et al. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer. Thyroid 2025.[67]
- Goichot B et al. Management of thyroid dysfunctions in the elderly — French Endocrine Society consensus 2019 guidelines. Ann Endocrinol 2020.[68]